Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24456344 | 0.87 | ALDH1A1 (0.43) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL2883737 | 0.87 | SLC6A3 (0.47) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL8714043 | 0.82 | SLC6A3 (0.35) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL8714046 | 0.82 | SLC6A3 (0.35) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL27292950 | 0.81 | SLC6A3 (0.44) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL7799394 | 0.79 | OPRM1 (0.31) | OPRM1OPRD1 | |
| SCHEMBL24087139 | 0.79 | LMNA (0.52) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL7808200 | 0.79 | OPRM1 (0.31) | OPRM1OPRD1 | |
| SCHEMBL2886888 | 0.78 | ALDH1A1 (0.47) | SLC6A3SLC6A2DRD2DRD4DRD3 | |
| SCHEMBL29346797 | 0.78 | GNAI3 (0.32) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
| US-4705858-A | ANTIEMETICS, DOPAMINE ANTAGONIST | BEECHAM GROUP P.L.C. (GB) | 1987-11-10 | — | — | US | disclosed |
| EP-0220339-A1 | Azabicycloalkyl derivatives | BEECHAM GROUP PLC (GB) | 1987-05-06 | — | — | EP | disclosed |
| US-4599420-A | GASTROINTESTINAL DISORDERS, ANTIEMETIC, PSYCHOSIS | BEECHAM GROUP LTD. (GB) | 1986-07-08 | — | — | US | disclosed |
| US-4544660-A | DOPAMINE ANTAGONIST | BEECHAM GROUP P.L.C. (GB) | 1985-10-01 | — | — | US | disclosed |
| EP-0013138-B1 | AZABICYCLOALKYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1983-12-07 | — | — | EP | disclosed |
| EP-0081054-A2 | Azabicyclo alkyl derivatives | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| US-4336259-A | DOPAMINE ANTAGONIST, NERVOUS SYSTEM DISORDERS AND GASTROINTESTINAL DISORDERS | BEECHAM GROUP LIMITED (GB) | 1982-06-22 | — | — | US | disclosed |
| US-4273778-A | TREATMENT OF GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, AND PSYCHOLOGICAL DISORDERS | BEECHAM GROUP, LIMITED (GB) | 1981-06-16 | — | — | US | disclosed |
| EP-0013138-A1 | Azabicycloalkyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | SLC6A3 30/4885SLC6A2 573/4885DRD2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.